Zobrazeno 1 - 10
of 62
pro vyhledávání: '"Nathalie Largeron"'
Autor:
C. Raina MacIntyre, J. Kevin Yin, Christian Felter, Robert I. Menzies, Edward Thommes, Nathalie Largeron, Aye M. Moa, Mallory Trent, Valentina Costantino, Seulki Choi, Fabián P. Alvarez
Publikováno v:
Vaccine: X, Vol 15, Iss , Pp 100365- (2023)
Background: Standard dose influenza vaccine provides moderate protection from infection, but with lower effectiveness among the elderly. High dose and adjuvanted vaccines (HD-TIV and aTIV) were developed to address this. This study aims to estimate t
Externí odkaz:
https://doaj.org/article/9be6f38f9364482fb3bc6700348632b0
Autor:
Francesco Saverio Mennini, Paolo Bonanni, Florence Bianic, Chiara de Waure, Gianluca Baio, Giacomo Plazzotta, Mathieu Uhart, Alessandro Rinaldi, Nathalie Largeron
Publikováno v:
Cost Effectiveness and Resource Allocation, Vol 15, Iss 1, Pp 1-14 (2017)
Abstract Background In Italy HPV vaccination with the quadrivalent vaccine (Gardasil®) is offered actively and free of charge to girls aged 12 since 2007. A nine-valent vaccine (Gardasil 9®) received the European market authorization in 2015 to pro
Externí odkaz:
https://doaj.org/article/a1cee773c6eb4b94ae65c032171d864c
Publikováno v:
BMC Public Health, Vol 17, Iss 1, Pp 1-18 (2017)
Abstract Background Due to the arrival of multi-valent HPV vaccines, it is more and more important to have a better understanding of the relationship between vaccination and screening programmes. This review aimed to: (1) collect published evidence o
Externí odkaz:
https://doaj.org/article/67f001d65a6440258029a037e5646967
Autor:
Stuart Carroll, Stuart Mealing, Fabián P. Alvarez, Ilana Gibbons, Nathalie Largeron, Richard Mattock, Joe Moss
Aims: High dose trivalent influenza vaccine (HD TIV) and adjuvant TIV (aTIV) have been developed specifically for adults aged 65 and older (65+) who are at high risk of life-threatening complications. However, there is a scarcity of evidence comparin
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2a2325facaf13afa425929b5feace0ef
https://eprints.whiterose.ac.uk/180449/1/13696998.2021.pdf
https://eprints.whiterose.ac.uk/180449/1/13696998.2021.pdf
Publikováno v:
Vaccine. 39
Introduction Due to waning immunity, adults aged ≥65 years are at increased risk of seasonal influenza infection and its complications. Adding to this risk, older adults have reduced responses to influenza vaccines. A high-dose trivalent inactivate
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::f4ee0be0530e74df56081e7d06b944f6
https://pubmed.ncbi.nlm.nih.gov/33518466
https://pubmed.ncbi.nlm.nih.gov/33518466
Publikováno v:
Expert Review of Pharmacoeconomics & Outcomes Research. 17:85-98
Introduction: Since 2007, the German Standing Vaccination Committee recommends HPV vaccination for girls aged 12–17 with a 2- (Cervarix®) or 4-valent (Gardasil®) vaccine. A 9-valent vaccine (Gardasil 9®) recently received a European market autho
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::36ec76a58afb023e084ba22ad1f3e772
https://doi.org/10.1080/14737167.2016.1208087
https://doi.org/10.1080/14737167.2016.1208087
Autor:
E. Préaud, Katharina Böhm, M. Uhart, F Bianic, Nathalie Largeron, Delphine Anger, Pamela Aidelsburger
Publikováno v:
Human Vaccines & Immunotherapeutics
Herpes zoster (HZ; shingles) is a common viral disease that affects the nerves and surrounding skin causing a painful dermatomal rash and leading to debilitating complications such as, mainly, post-herpetic neuralgia (PHN). Currently, there is no eff
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9b2cfe5e3f655b4d109f48755f70baf0
https://doi.org/10.1080/21645515.2015.1011561
https://doi.org/10.1080/21645515.2015.1011561
Autor:
Paolo Bonanni, Alessandro Rinaldi, M. Uhart, F Bianic, Francesco Saverio Mennini, Chiara De Waure, Giacomo Plazzotta, Gianluca Baio, Nathalie Largeron
Publikováno v:
Cost Effectiveness and Resource Allocation, Vol 15, Iss 1, Pp 1-14 (2017)
Cost Effectiveness and Resource Allocation : C/E
Cost Effectiveness and Resource Allocation : C/E
Background In Italy HPV vaccination with the quadrivalent vaccine (Gardasil®) is offered actively and free of charge to girls aged 12 since 2007. A nine-valent vaccine (Gardasil 9®) received the European market authorization in 2015 to protect, wit
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2cde08294f286bf7c64a627d13264ed2
https://doi.org/10.1186/s12962-017-0073-8
https://doi.org/10.1186/s12962-017-0073-8
Publikováno v:
Vaccine. 32:1645-1653
Objective The objective of this study was to systematically review cost-effectiveness studies of vaccination against herpes zoster (HZ) and postherpetic neuralgia (PHN). Methods We searched MEDLINE and EMBASE databases for eligible studies published
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::995217faa6e69ff33887c9e765c1af5c
https://doi.org/10.1016/j.vaccine.2014.01.058
https://doi.org/10.1016/j.vaccine.2014.01.058
Publikováno v:
Value in Health. 22:S643
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c76000e4d40bd032062dc555e54ae690
https://doi.org/10.1016/j.jval.2019.09.1264
https://doi.org/10.1016/j.jval.2019.09.1264